News and Press Releases

PCI Pharma Services to Acquire US-based Aseptic Fill-Finish CDMO Ajinomoto Althea

Acquisition creates a world-class large-scale manufacturing hub in San Diego region with state-of-the-art aseptic facilities for prefilled syringes, cartridges and high potent formulations such as ADCs, complementing existing global sterile...

Category: Logistics, Manufacturing and Packing, Pharmaceutical
Posted: April 24, 2025

3001 Red Lion Road, Philadelphia, PA 19114, USA

CARBOGEN AMCIS Shanghai Site Awarded Drug Manufacturing License from Chinese NMPA

22 April 2025 -- Bubendorf, Switzerland -- CARBOGEN AMCIS, a Switzerland-based pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, is pleased to announce that its Shanghai facility has...

Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: April 22, 2025

Hauptstrasse 171 CH-4416 Bubendorf Switzerland

ViroCell manufactured a GMP lentiviral vector for UCL to accelerate research into prevention of relapse in childhood blood cancer

UCL leveraged ViroCell’s expertise in lentiviral vector manufacturing for an innovative CAR T-cell therapy for the treatment of paediatric acute lymphoblastic leukaemia 17 April 2025 -- London, UK and New...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 17, 2025

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

First and only EZH2 inhibitor approved by the NMPA HUTCHMED’s fourth product, and its first approval in hematological malignancies. 21 March 2025 -- Hong Kong, Shanghai & New Jersey, US...

Category:
Posted: March 21, 2025

48th Floor, Cheung Kong Center 2 Queen's Road Central, Hong Kong

Micreos Pharmaceuticals partners with Biologics CDMO Northway Biotech for its Engineered Endolysin therapeutic manufacturing program

4 March 2025 -- Zug, Switzerland, and Vilnius, Lithuania -- Micreos Pharmaceuticals AG ("Micreos"), a preclinical-stage biopharmaceutical company, specializing in developing Engineered Endolysin therapies to target harmful pathogens that cause...

Category: BioManufacturing, Biotechnology, Other, Pharmaceutical
Posted: March 4, 2025

Veranova Relocates Headquarters to Devens, MA

3 March – Devens, MA, US – Veranova is pleased to announce the move of its corporate headquarters to its Devens, Massachusetts facility, one of the company’s principal sites for...

Category: Drug Discovery, Manufacturing and Packing
Posted: March 4, 2025

25 Patton Road, Devens, MA 10434, US

ProBioGen Launches New Website to Enhance User Experience and Streamline Access to Expanded

February 04, 2025 – Berlin, Germany – Biotech Newswire / -- ProBioGen has launched its new, redesigned website to provide biotech and biopharma professionals with clear access to its expanded...

Category: Biotechnology
Posted: February 5, 2025

Herbert-Bayer-Straße 8 13086 Berlin

CARBOGEN AMCIS Announces Leadership Transition

3 February 2025 – Bubendorf, Switzerland –Switzerland-based CARBOGEN AMCIS, a leading pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, has announced the departure of its current CEO, Pascal...

Category:
Posted: February 3, 2025

Hauptstrasse 171 CH-4416 Bubendorf Switzerland

Rentschler Biopharma announces strategic realignment of its global business operations

30 January 2025 – Laupheim, Germany – Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced today a realignment of its global business operations...

Category: BioManufacturing
Posted: January 30, 2025

Erwin-Rentschler-Str. 21 88471 Laupheim Germany

Swissmedic Inspection Success Highlights Excellence at CARBOGEN AMCIS Vionnaz Site

January 13 2025 – Bubendorf, Switzerland — Switzerland-based CARBOGEN AMCIS, a leading pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, is pleased to announce the successful completion of...

Category: Pharmaceutical
Posted: January 16, 2025

Hauptstrasse 171 CH-4416 Bubendorf Switzerland

HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Indication expands to include treatment-naïve patients The 2021 conditional approval in previously treated patients converted to full approval. 14 January 2025 -- Hong Kong, Shanghai, and New Jersey, US --...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 14, 2025

48th Floor, Cheung Kong Center 2 Queen's Road Central, Hong Kong

Swissmedic Inspection Success Highlights Excellence at CARBOGEN AMCIS Vionnaz Site

13 January 2025 -- Bubendorf, Switzerland -- Switzerland-based CARBOGEN AMCIS, a leading pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, is pleased to announce the successful completion of a Swissmedic...

Category: BioManufacturing, Manufacturing and Packing, Other, Pharmaceutical
Posted: January 13, 2025

Hauptstrasse 171 CH-4416 Bubendorf Switzerland

Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma

Approval based on positive pivotal ICARIA-MM phase 3 study using the China-based IsaFiRsT real-world study as bridging data, which demonstrated Sarclisa and the standard treatment Pd, improved responses and long-term...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 13, 2025

One Onslow Street, Guildford, Surrey, GU1 4YS, UK

Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy

China’s National Medical Products Administration (NMPA) approved AGAMREE® for the treatment of Duchenne muscular dystrophy in patients aged 4 years and older This approval makes AGAMREE the first and only...

Category: Other, Pharmaceutical
Posted: December 11, 2024

Santhera Pharmaceuticals Headquarters Hohenrainstrasse 24 | 4133 Pratteln | Switzerland

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

First regulatory approval for fruquintinib combination therapy with an immune checkpoint inhibitor 3 December 2024 -- Hong Kong, Shanghai and New Jersey, US — HUTCHMED (China) and Innovent Biologics, Inc...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 3, 2024

48th Floor, Cheung Kong Center 2 Queen's Road Central, Hong Kong